The CIC contributes to the creation of white papers, response documents, and peer-reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.
Publications prior to 2010 are credited to the Cancer Vaccine Cnsortium, the former name of the Cancer Immunotherapy Consortium
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
We introduce you to Rafael Amado, M.D., chief medical officer at Adaptimmune, a leader in T cell receptor (TCR) cancer immunotherapy.
On June 30, 2018, over 200 patients, caregivers, and advocates gathered to connect with experts and learn about the science of cancer immunotherapy in San Francisco.